superior promace-cytabom promace-mopp treatment advanc diffus aggress lymphoma result prospect trial erratum clin oncol apr ninety-thre patient stage II iii IV follicular large-cel large-cel diffus mix immunoblast small noncleaved-cel non-burkitt lymphoma cyclophosphamid IV IV IV day mechlorethamin IV vincristin cap mg total dose IV day prednison daili day procarbazin daili day IV day leucovorin hour dose hour methotrex cycl day promace-mopp treatment promace-mopp cytarabin IV IV vincristin cap mg total dose IV IV day hour dose hour methotrex daili day cycl day promace-cytabom co-trimoxazol double-strength tablet period treatment promace-cytabom regimen risk pneumocysti carinii pneumonia first patient combin median follow-up year patient promace-mopp complet remiss CR complet respond patient treatment-rel caus patient promace-cytabom CR complet respond patient complet respons rate surviv patient promace-cytabom mortal promace-cytabom treatment overal patient treatment-rel mortal patient prophylact co-trimoxazol promace-cytabom combin chemotherapi co-trimoxazol prophylaxi safe effect treatment patient aggress histolog malign lymphoma superior promace-mopp 